Interferon-inducible antiviral effectors

Anthony J Sadler, Bryan R G Williams, Anthony J Sadler, Bryan R G Williams

Abstract

Since the discovery of interferons (IFNs), considerable progress has been made in describing the nature of the cytokines themselves, the signalling components that direct the cell response and their antiviral activities. Gene targeting studies have distinguished four main effector pathways of the IFN-mediated antiviral response: the Mx GTPase pathway, the 2',5'-oligoadenylate-synthetase-directed ribonuclease L pathway, the protein kinase R pathway and the ISG15 ubiquitin-like pathway. As discussed in this Review, these effector pathways individually block viral transcription, degrade viral RNA, inhibit translation and modify protein function to control all steps of viral replication. Ongoing research continues to expose additional activities for these effector proteins and has revealed unanticipated functions of the antiviral response.

Figures

Figure 1. Interferon receptor signalling.
Figure 1. Interferon receptor signalling.
The action of the interferons (IFNs) is mediated through three receptor complexes: a heterodimer of IFNα receptor 1 (IFNAR1) and IFNAR2 binds type I IFNs; the interleukin-10 receptor 2 (IL-10R2) associates with IFNLR1 (IFNλ receptor 1) to bind the three IFNλ subtypes; and a tetramer consisting of two IFNGR2 (IFNγ receptor 2) chains and two IFNGR1 chains binds dimers of the type II IFNγ. Following binding by type I IFNs, signal transduction is initiated by pre-associated tyrosine kinases (JAK1 and TYK2 (tyrosine kinase 2)), which phosphorylate IFNAR1 and leads to the recruitment and phosphorylation of the signal transducers and activators of transcription (STATs). STAT heterodimers associate with IFN-regulatory factor 9 (IRF9) to form IFN-stimulated gene factor 3 (ISGF3), or STAT homodimers to form the IFNγ activation factor (GAF). These complexes translocate to the nucleus to induce IFN-stimulated genes from IFN-stimulated response elements (ISREs) or GAS promoter elements, for type I and type III, or type II IFN responses, respectively. Divergence from this simplified signalling pathway can occur, for example, type I IFNs are reported to elicit STAT homodimers, and more complicated interplay, with activation of other STAT proteins, occurs than is shown here. ISG15, IFN-stimulated protein of 15 kDa; Mx, myxovirus resistance; OAS, 2′,5′-oligoadenylate synthetase; PKR, protein kinase R.
Figure 2. Domain structure of antiviral proteins.
Figure 2. Domain structure of antiviral proteins.
a | Interferon-stimulated protein of 15 kDa (ISG15) contains two ubiquitin-like (UBL) domains. The C-terminal UBL encodes conserved hydrophobic patches, charged pockets (indicated by vertical bars) and diglycine residues similar to ubiquitin and other ubiquitin-like proteins. Accordingly, the C-terminal UBL is sufficient for activation and transfer of ISG15 to E1 and E2 enzymes. However, the N-terminal UBL seems to be necessary for E3-mediated conjugation to protein substrates. b | The distinguishing features of the dynamin protein family of Mx GTPases are the large GTP-binding domain (DYNc) that contains three consensus GTP-binding elements (not indicated) and a self-assembly sequence (SAS), the central interactive domain (CID), and the C-terminal leucine zipper (LZ). The LZ region contains a coiled-coil (CC) domain at its C terminus that forms bundles of α-helices involved in protein–protein interactions. c | The 2′,5′-oligoadenylate synthetase 1 (OAS1), OAS2 and OAS3 proteins contain 1, 2 or 3 copies respectively, of the OAS domains. Duplicated OAS domains in OAS2 and OAS3, and the single domain in OASL (OAS-like) are catalytically inactive (shown in red). The C-termini of all the OAS proteins are variable, with OASL also encoding a unique UBL domain. The OAS domain produces 2′,5′-oligoadenylates that activate ribonuclease L (RNaseL). RNaseL has eight N-terminal ankyrin repeats (ANK), which mediate protein–protein interactions, and two kinase-like domains, a Ser/Thr/Tyr kinase (STYKc) and a PUG domain that are found in some kinases and several other nuclear proteins. However, neither domain has functional kinase activity. d |Protein kinase R (PKR) contains two repeated RNA-binding motifs (RBMs), which together constitute the N-terminal RNA-binding domain. On binding of viral RNA, steric inhibition of enzyme activity is relieved, leading to the activation of the C-terminal serine/threonine protein kinase domain (S/T-kinase).
Figure 3. Mechanism of action of ISG15.
Figure 3. Mechanism of action of ISG15.
The expression of interferon (IFN)-stimulated protein of 15 kDa (ISG15), the E1-activating enzyme UBE1L (E1-like ubiquitin-activating enzyme) and multiple E2-conjugating enzymes (shown here as an example is UBCH8) and E3-ligase enzymes (such as HERC5 (homologous to the E6-associated protein C terminus domain and RCC1-like domain containing protein 5)) is coordinately induced by type I IFNs through IFN-stimulated response elements (ISREs) in their respective gene promoter regions. E1, E2 and E3 proteins sequentially catalyse the conjugation of ISG15 to numerous protein substrates to modulate pleiotropic cellular responses to inhibit virus production. This process (known as ISGylation) is reversibly regulated by proteases (such as ubiquitin-specific protease 18 (USP18)), which are also induced by IFNs.
Figure 4. Mechanism of action of MxA.
Figure 4. Mechanism of action of MxA.
Following stimulation with type I interferons (IFNs), MXA (myxovirus-resistance A) gene expression is induced through an IFN-stimulated response element (ISRE) in the gene promoter. The MxA protein accumulates in the cytoplasm on intracellular membranes (such as the endoplasmic reticulum, ER) as oligomers formed by association between the leucine zipper (LZ) domain and central interactive domain of the protein. Following viral infection, MxA monomers are released and bind viral nucleocapsids or other viral components, to trap and then degrade them.
Figure 5. The OAS1–RNaseL antiviral pathway.
Figure 5. The OAS1–RNaseL antiviral pathway.
2′,5′-oligoadenylate synthetase 1 (OAS1) is expressed at low constitutive levels and is upregulated by type I interferons (IFNs). OAS1 protein accumulates in the cell cytoplasm as an inactive monomer. Following activation by viral double-stranded RNA (dsRNA), the enzyme oligomerizes to form a tetramer that synthesizes 2′,5′-oligoadenylates that, in turn, activate the constitutively expressed inactive ribonuclease L (RNaseL). The binding of 2′,5′-oligoadenylates to RNaseL triggers the dimerization of enzyme monomers, through their kinase-like domains, and this then enables RNAseL to cleave cellular (and viral) RNAs. ISRE, IFN-stimulated response element.
Figure 6. Mechanism of action of PKR.
Figure 6. Mechanism of action of PKR.
Protein kinase R (PKR) is constitutively expressed, and is also induced by type I interferons (IFNs) under the control of a kinase conserved sequence (KCS) and IFN-stimulated response element (ISRE) in the promoter of PKR. The kinase accumulates in the nucleus and cytoplasm as an inactive monomer, which is activated directly by viral RNAs, and by several other ligands, such as ceramide or the protein activator PACT (protein activator of the IFN-inducible protein kinase). Following activation, PKR monomers are phosphorylated and dimerize to form the active enzyme. Activated PKR regulates several cell signalling pathways through mechanisms that have not been fully explained, but a crucial function of PKR in viral defence is the inhibition of translation by phosphorylation of eukaryotic translation initiation factor 2α (EIF2α).

References

    1. Isaacs A, Lindenmann J. Virus interference. I. The interferon. Proc. R. Soc. Lond. [Biol.] 1957;147:258–267. doi: 10.1098/rspb.1957.0048.
    1. Borden EC, et al. Interferons at age 50: past, current and future impact on biomedicine. Nature Rev. Drug Discov. 2007;6:975–990. doi: 10.1038/nrd2422.
    1. Levraud JP, et al. Identification of the zebrafish IFN receptor: implications for the origin of the vertebrate IFN system. J. Immunol. 2007;178:4385–4394. doi: 10.4049/jimmunol.178.7.4385.
    1. O'Connell RM, et al. Type I interferon production enhances susceptibility to Listeria monocytogenes infection. J. Exp. Med. 2004;200:437–445. doi: 10.1084/jem.20040712.
    1. Muller U, et al. Functional role of type I and type II interferons in antiviral defense. Science. 1994;264:1918–1921. doi: 10.1126/science.8009221.
    1. Casrouge A, et al. Herpes simplex virus encephalitis in human UNC-93B deficiency. Science. 2006;314:308–312. doi: 10.1126/science.1128346.
    1. Dupuis S, et al. Impaired response to interferon-α/β and lethal viral disease in human STAT1 deficiency. Nature Genet. 2003;33:388–391. doi: 10.1038/ng1097.
    1. Jouanguy E, et al. Human primary immunodeficiencies of type I interferons. Biochimie. 2007;89:878–883. doi: 10.1016/j.biochi.2007.04.016.
    1. Minegishi Y, et al. Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. Immunity. 2006;25:745–755. doi: 10.1016/j.immuni.2006.09.009.
    1. Der SD, Zhou A, Williams BR, Silverman RH. Identification of genes differentially regulated by interferon α, β, or γ using oligonucleotide arrays. Proc. Natl Acad. Sci. USA. 1998;95:15623–15628. doi: 10.1073/pnas.95.26.15623.
    1. Pedersen IM, et al. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature. 2007;449:919–922. doi: 10.1038/nature06205.
    1. Blomstrom DC, Fahey D, Kutny R, Korant BD, Knight E., Jr. Molecular characterization of the interferon-induced 15-kDa protein. Molecular cloning and nucleotide and amino acid sequence. J. Biol. Chem. 1986;261:8811–8816.
    1. Loeb KR, Haas AL. The interferon-inducible 15-kDa ubiquitin homolog conjugates to intracellular proteins. J. Biol. Chem. 1992;267:7806–7813.
    1. Liu YC, Penninger J, Karin M. Immunity by ubiquitylation: a reversible process of modification. Nature Rev. Immunol. 2005;5:941–952. doi: 10.1038/nri1731.
    1. Narasimhan J, Potter JL, Haas AL. Conjugation of the 15-kDa interferon-induced ubiquitin homolog is distinct from that of ubiquitin. J. Biol. Chem. 1996;271:324–330. doi: 10.1074/jbc.271.1.324.
    1. Yuan W, Krug RM. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J. 2001;20:362–371. doi: 10.1093/emboj/20.3.362.
    1. Takeuchi T, Iwahara S, Saeki Y, Sasajima H, Yokosawa H. Link between the ubiquitin conjugation system and the ISG15 conjugation system: ISG15 conjugation to the UbcH6 ubiquitin E2 enzyme. J. Biochem. (Tokyo) 2005;138:711–719. doi: 10.1093/jb/mvi172.
    1. Zhao C, et al. The UbcH8 ubiquitin E2 enzyme is also the E2 enzyme for ISG15, an IFN-αβ-induced ubiquitin-like protein. Proc. Natl Acad. Sci. USA. 2004;101:7578–7582. doi: 10.1073/pnas.0402528101.
    1. Kim KI, Giannakopoulos NV, Virgin HW, Zhang DE. Interferon-inducible ubiquitin E2, Ubc8, is a conjugating enzyme for protein ISGylation. Mol. Cell Biol. 2004;24:9592–9600. doi: 10.1128/MCB.24.21.9592-9600.2004.
    1. Wong JJ, Pung YF, Sze NS, Chin KC. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc. Natl Acad. Sci. USA. 2006;103:10735–10740. doi: 10.1073/pnas.0600397103.
    1. Zou W, Zhang DE. The interferon-inducible ubiquitin-protein isopeptide ligase (E3) EFP also functions as an ISG15 E3 ligase. J. Biol. Chem. 2006;281:3989–3994. doi: 10.1074/jbc.M510787200.
    1. Catic A, et al. Screen for ISG15-crossreactive deubiquitinases. PLoS ONE. 2007;2:e679. doi: 10.1371/journal.pone.0000679.
    1. Malakhov MP, Malakhova OA, Kim KI, Ritchie KJ, Zhang DE. UBP43 (USP18) specifically removes ISG15 from conjugated proteins. J. Biol. Chem. 2002;277:9976–9981. doi: 10.1074/jbc.M109078200.
    1. Zhao C, Denison C, Huibregtse JM, Gygi S, Krug RM. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc. Natl Acad. Sci. USA. 2005;102:10200–10205. doi: 10.1073/pnas.0504754102.
    1. Giannakopoulos NV, et al. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem. Biophys. Res. Commun. 2005;336:496–506. doi: 10.1016/j.bbrc.2005.08.132.
    1. Takeuchi T, Yokosawa H. Detection and analysis of protein ISGylation. Methods Mol. Biol. 2008;446:139–149. doi: 10.1007/978-1-60327-084-7_10.
    1. Lu G, et al. ISG15 enhances the innate antiviral response by inhibition of IRF-3 degradation. Cell. Mol. Biol. 2006;52:29–41.
    1. Okumura F, Zou W, Zhang DE. ISG15 modification of the eIF4E cognate 4EHP enhances cap structure-binding activity of 4EHP. Genes Dev. 2007;21:255–260. doi: 10.1101/gad.1521607.
    1. Takeuchi T, Kobayashi T, Tamura S, Yokosawa H. Negative regulation of protein phosphatase 2Cβ by ISG15 conjugation. FEBS Lett. 2006;580:4521–4526. doi: 10.1016/j.febslet.2006.07.032.
    1. D'Cunha J, et al. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J. Immunol. 1996;157:4100–4108.
    1. Majetschak M, et al. Extracellular ubiquitin inhibits the TNF-α response to endotoxin in peripheral blood mononuclear cells and regulates endotoxin hyporesponsiveness in critical illness. Blood. 2003;101:1882–1890. doi: 10.1182/blood-2002-03-0918.
    1. Sakai N, Sawada H, Yokosawa H. Extracellular ubiquitin system implicated in fertilization of the ascidian, Halocynthia roretzi: isolation and characterization. Dev. Biol. 2003;264:299–307. doi: 10.1016/j.ydbio.2003.07.016.
    1. Lenschow DJ, et al. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J. Virol. 2005;79:13974–13983. doi: 10.1128/JVI.79.22.13974-13983.2005.
    1. Osiak A, Utermohlen O, Niendorf S, Horak I, Knobeloch KP. ISG15, an interferon-stimulated ubiquitin-like protein, is not essential for STAT1 signaling and responses against vesicular stomatitis and lymphocytic choriomeningitis virus. Mol. Cell Biol. 2005;25:6338–6345. doi: 10.1128/MCB.25.15.6338-6345.2005.
    1. Lenschow DJ, et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc. Natl Acad. Sci. USA. 2007;104:1371–1376. doi: 10.1073/pnas.0607038104.
    1. Zhang Y, Burke CW, Ryman KD, Klimstra WB. Identification and characterization of interferon-induced proteins that inhibit alphavirus replication. J. Virol. 2007;81:11246–11255. doi: 10.1128/JVI.01282-07.
    1. Kim KI, et al. Ube1L and protein ISGylation are not essential for α/β interferon signaling. Mol. Cell Biol. 2006;26:472–479. doi: 10.1128/MCB.26.2.472-479.2006.
    1. Malakhova OA, Zhang DE. ISG15 inhibits Nedd4 ubiquitin E3 activity and enhances the innate antiviral response. J. Biol. Chem. 2008;283:8783–8787. doi: 10.1074/jbc.C800030200.
    1. Okumura A, Lu G, Pitha-Rowe I, Pitha PM. Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15. Proc. Natl Acad. Sci. USA. 2006;103:1440–1445. doi: 10.1073/pnas.0510518103.
    1. Chang YG, et al. Different roles for two ubiquitin-like domains of ISG15 in protein modification. J. Biol. Chem. 2008;283:13370–13377. doi: 10.1074/jbc.M800162200.
    1. Arguello MD, Hiscott J. Ub surprised: viral ovarian tumor domain proteases remove ubiquitin and ISG15 conjugates. Cell Host Microbe. 2007;2:367–369. doi: 10.1016/j.chom.2007.11.005.
    1. Frias-Staheli N, et al. Ovarian tumor domain-containing viral proteases evade ubiquitin- and ISG15-dependent innate immune responses. Cell Host Microbe. 2007;2:404–416. doi: 10.1016/j.chom.2007.09.014.
    1. Lindner HA, et al. Selectivity in ISG15 and ubiquitin recognition by the SARS coronavirus papain-like protease. Arch. Biochem. Biophys. 2007;466:8–14. doi: 10.1016/j.abb.2007.07.006.
    1. MacMicking JD. IFN-inducible GTPases and immunity to intracellular pathogens. Trends Immunol. 2004;25:601–609. doi: 10.1016/j.it.2004.08.010.
    1. Haller O, Arnheiter H, Lindenmann J, Gresser I. Host gene influences sensitivity to interferon action selectively for influenza virus. Nature. 1980;283:660–662. doi: 10.1038/283660a0.
    1. Haller O, Arnheiter H, Gresser I, Lindenmann J. Genetically determined, interferon-dependent resistance to influenza virus in mice. J. Exp. Med. 1979;149:601–612. doi: 10.1084/jem.149.3.601.
    1. Lindenmann J. Resistance of mice to mouse adapted myxoviruses. Virology. 1962;16:203–204. doi: 10.1016/0042-6822(62)90297-0.
    1. Lindenmann J. Inheritance of resistance to influenza virus in mice. Proc. Soc. Exp. Biol. Med. 1964;116:506–509. doi: 10.3181/00379727-116-29292.
    1. Arnheiter H, Skuntz S, Noteborn M, Chang S, Meier E. Transgenic mice with intracellular immunity to influenza virus. Cell. 1990;62:51–61. doi: 10.1016/0092-8674(90)90239-B.
    1. Aebi M, et al. cDNA structures and regulation of two interferon-induced human Mx proteins. Mol. Cell Biol. 1989;9:5062–5072. doi: 10.1128/MCB.9.11.5062.
    1. Horisberger MA, et al. cDNA cloning and assignment to chromosome 21 of IFI-78K gene, the human equivalent of murine Mx gene. Somat. Cell. Mol. Genet. 1988;14:123–131. doi: 10.1007/BF01534397.
    1. Haller O, Frese M, Rost D, Nuttall PA, Kochs G. Tick-borne thogoto virus infection in mice is inhibited by the orthomyxovirus resistance gene product Mx1. J. Virol. 1995;69:2596–2601.
    1. Andersson I, et al. Human MxA protein inhibits the replication of Crimean-Congo hemorrhagic fever virus. J. Virol. 2004;78:4323–4329. doi: 10.1128/JVI.78.8.4323-4329.2004.
    1. Chieux V, et al. Inhibition of coxsackievirus B4 replication in stably transfected cells expressing human MxA protein. Virology. 2001;283:84–92. doi: 10.1006/viro.2001.0877.
    1. Gordien E, et al. Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J. Virol. 2001;75:2684–2691. doi: 10.1128/JVI.75.6.2684-2691.2001.
    1. Hijikata M, Ohta Y, Mishiro S. Identification of a single nucleotide polymorphism in the MxA gene promoter (G/T at nt -88) correlated with the response of hepatitis C patients to interferon. Intervirology. 2000;43:124–127. doi: 10.1159/000025035.
    1. Suzuki F, et al. Single nucleotide polymorphism of the MxA gene promoter influences the response to interferon monotherapy in patients with hepatitis C viral infection. J. Viral Hepat. 2004;11:271–276. doi: 10.1111/j.1365-2893.2004.00509.x.
    1. Torisu H, et al. Functional MxA promoter polymorphism associated with subacute sclerosing panencephalitis. Neurology. 2004;62:457–460. doi: 10.1212/01.WNL.0000106940.95749.8E.
    1. Fernandez M, et al. In vivo and in vitro induction of MxA protein in peripheral blood mononuclear cells from patients chronically infected with hepatitis C virus. J. Infect. Dis. 1999;180:262–267. doi: 10.1086/314859.
    1. Kochs G, Haller O. Interferon-induced human MxA GTPase blocks nuclear import of Thogoto virus nucleocapsids. Proc. Natl Acad. Sci. USA. 1999;96:2082–2086. doi: 10.1073/pnas.96.5.2082.
    1. Accola MA, Huang B, Al Masri A, McNiven MA. The antiviral dynamin family member, MxA, tubulates lipids and localizes to the smooth endoplasmic reticulum. J. Biol. Chem. 2002;277:21829–21835. doi: 10.1074/jbc.M201641200.
    1. Turan K, et al. Nuclear MxA proteins form a complex with influenza virus NP and inhibit the transcription of the engineered influenza virus genome. Nucleic Acids Res. 2004;32:643–652. doi: 10.1093/nar/gkh192.
    1. Grimm D, et al. Replication fitness determines high virulence of influenza A virus in mice carrying functional Mx1 resistance gene. Proc. Natl Acad. Sci. USA. 2007;104:6806–6811. doi: 10.1073/pnas.0701849104.
    1. Fernandez M, Quiroga JA, Carreno V. Hepatitis B virus downregulates the human interferon-inducible MxA promoter through direct interaction of precore/core proteins. J. Gen. Virol. 2003;84:2073–2082. doi: 10.1099/vir.0.18966-0.
    1. Hoenen A, Liu W, Kochs G, Khromykh AA, Mackenzie JM. West Nile virus-induced cytoplasmic membrane structures provide partial protection against the interferon-induced antiviral MxA protein. J. Gen. Virol. 2007;88:3013–3017. doi: 10.1099/vir.0.83125-0.
    1. Kerr IM, Brown RE, Hovanessian AG. Nature of inhibitor of cell-free protein synthesis formed in response to interferon and double-stranded RNA. Nature. 1977;268:540–542. doi: 10.1038/268540a0.
    1. Rebouillat D, Hovanessian AG. The human 2′,5′-oligoadenylate synthetase family: interferon-induced proteins with unique enzymatic properties. J. Interferon Cytokine Res. 1999;19:295–308. doi: 10.1089/107999099313992.
    1. Clemens MJ, Williams BRG. Inhibition of cell-free protein synthesis by pppA2′p5′A2′p5′A: a novel oligonucleotide synthesized by interferon-treated L cell extracts. Cell. 1978;13:565–572. doi: 10.1016/0092-8674(78)90329-X.
    1. Malathi K, Dong B, Gale M, Jr, Silverman RH. Small self-RNA generated by RNase L amplifies antiviral innate immunity. Nature. 2007;448:816–819. doi: 10.1038/nature06042.
    1. Hovanessian AG, Justesen J. The human 2′-5′oligoadenylate synthetase family: unique interferon-inducible enzymes catalyzing 2′-5′ instead of 3′-5′ phosphodiester bond formation. Biochimie. 2007;89:779–788. doi: 10.1016/j.biochi.2007.02.003.
    1. Andersen JB, Strandbygard DJ, Hartmann R, Justesen J. Interaction between the 2′-5′ oligoadenylate synthetase-like protein p59 OASL and the transcriptional repressor methyl CpG-binding protein 1. Eur. J. Biochem. 2004;271:628–636. doi: 10.1046/j.1432-1033.2003.03966.x.
    1. Marie I, Svab J, Robert N, Galabru J, Hovanessian AG. Differential expression and distinct structure of 69- and 100-kDa forms of 2–5A synthetase in human cells treated with interferon. J. Biol. Chem. 1990;265:18601–18607.
    1. Ghosh A, Sarkar SN, Guo W, Bandyopadhyay S, Sen GC. Enzymatic activity of 2′-5′-oligoadenylate synthetase is impaired by specific mutations that affect oligomerization of the protein. J. Biol. Chem. 1997;272:33220–33226. doi: 10.1074/jbc.272.52.33220.
    1. Hartmann R, Justesen J, Sarkar SN, Sen GC, Yee VC. Crystal structure of the 2′-specific and double-stranded RNA-activated interferon-induced antiviral protein 2′-5′-oligoadenylate synthetase. Mol. Cell. 2003;12:1173–1185. doi: 10.1016/S1097-2765(03)00433-7.
    1. Sarkar SN, Pal S, Sen GC. Crisscross enzymatic reaction between the two molecules in the active dimeric P69 form of the 2′-5′ oligodenylate synthetase. J. Biol. Chem. 2002;277:44760–44764. doi: 10.1074/jbc.M207126200.
    1. Dong B, et al. Intrinsic molecular activities of the interferon-induced 2-5A-dependent RNase. J. Biol. Chem. 1994;269:14153–14158.
    1. Castora FJ, Erickson CE, Kovacs T, Lesiak K, Torrence PF. 2′,5′-oligoadenylates inhibit relaxation of supercoiled DNA by calf thymus DNA topoisomerase I. J. Interferon Res. 1991;11:143–149. doi: 10.1089/jir.1991.11.143.
    1. Silverman RH. Viral encounters with 2′,5′-oligoadenylate synthetase and RNase L during the interferon antiviral response. J. Virol. 2007;81:12720–12729. doi: 10.1128/JVI.01471-07.
    1. Nakanishi M, Goto Y, Kitade Y. 2–5A induces a conformational change in the ankyrin-repeat domain of RNase L. Proteins. 2005;60:131–138. doi: 10.1002/prot.20474.
    1. Floyd-Smith G, Slattery E, Lengyel P. Interferon action: RNA cleavage pattern of a (2′-5′)oligoadenylate-dependent endonuclease. Science. 1981;212:1030–1032. doi: 10.1126/science.6165080.
    1. Wreschner DH, McCauley JW, Skehel JJ, Kerr IM. Interferon action–sequence specificity of the ppp(A2′p)nA-dependent ribonuclease. Nature. 1981;289:414–417. doi: 10.1038/289414a0.
    1. Zhou A, et al. Interferon action and apoptosis are defective in mice devoid of 2′, 5′-oligoadenylate-dependent RNase L. EMBO J. 1997;16:6355–6363. doi: 10.1093/emboj/16.21.6355.
    1. Xiang Y, et al. Blockade of interferon induction and action by the E3L double-stranded RNA binding proteins of vaccinia virus. J. Virol. 2002;76:5251–5259. doi: 10.1128/JVI.76.10.5251-5259.2002.
    1. Bonnevie-Nielsen V, et al. Variation in antiviral 2′, 5′-oligoadenylate synthetase (2′5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am. J. Hum. Genet. 2005;76:623–633. doi: 10.1086/429391.
    1. Yakub I, et al. Single nucleotide polymorphisms in genes for 2′-5′-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J. Infect. Dis. 2005;192:1741–1748. doi: 10.1086/497340.
    1. Sperling J, et al. Possible involvement of (2′5′)oligoadenylate synthetase activity in pre-mRNA splicing. Proc. Natl Acad. Sci. USA. 1991;88:10377–10381. doi: 10.1073/pnas.88.23.10377.
    1. Meurs E, et al. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell. 1990;62:379–390. doi: 10.1016/0092-8674(90)90374-N.
    1. Roberts WK, Hovanessian A, Brown RE, Clemens MJ, Kerr IM. Interferon-mediated protein kinase and low-molecular-weight inhibitor of protein synthesis. Nature. 1976;264:477–480. doi: 10.1038/264477a0.
    1. Dar AC, Dever TE, Sicheri F. Higher-order substrate recognition of eIF2α by the RNA-dependent protein kinase PKR. Cell. 2005;122:887–900. doi: 10.1016/j.cell.2005.06.044.
    1. Ank N, et al. λ interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J. Virol. 2006;80:4501–4509. doi: 10.1128/JVI.80.9.4501-4509.2006.
    1. Gelev V, et al. Mapping of the auto-inhibitory interactions of protein kinase R by nuclear magnetic resonance. J. Mol. Biol. 2006;364:352–363. doi: 10.1016/j.jmb.2006.08.077.
    1. Nanduri S, Rahman F, Williams BR, Qin J. A dynamically tuned double-stranded RNA binding mechanism for the activation of antiviral kinase PKR. EMBO J. 2000;19:5567–5574. doi: 10.1093/emboj/19.20.5567.
    1. George CX, Thomis DC, McCormack SJ, Svahn CM, Samuel CE. Characterization of the heparin-mediated activation of PKR, the interferon-inducible RNA-dependent protein kinase. Virology. 1996;221:180–188. doi: 10.1006/viro.1996.0364.
    1. Ruvolo PP, Gao F, Blalock WL, Deng X, May WS. Ceramide regulates protein synthesis by a novel mechanism involving the cellular PKR activator RAX. J. Biol. Chem. 2001;276:11754–11758. doi: 10.1074/jbc.M011400200.
    1. Patel RC, Sen GC. PACT, a protein activator of the interferon-induced protein kinase, PKR. EMBO J. 1998;17:4379–4390. doi: 10.1093/emboj/17.15.4379.
    1. Dey M, et al. Mechanistic link between PKR dimerization, autophosphorylation, and eIF2α substrate recognition. Cell. 2005;122:901–913. doi: 10.1016/j.cell.2005.06.041.
    1. Romano PR, et al. Autophosphorylation in the activation loop is required for full kinase activity in vivo of human and yeast eukaryotic initiation factor 2α kinases PKR and GCN2. Mol. Cell Biol. 1998;18:2282–2297. doi: 10.1128/MCB.18.4.2282.
    1. Taylor DR, et al. Autophosphorylation sites participate in the activation of the double-stranded-RNA-activated protein kinase PKR. Mol. Cell Biol. 1996;16:6295–6302. doi: 10.1128/MCB.16.11.6295.
    1. Nanduri S, Carpick BW, Yang Y, Williams BR, Qin J. Structure of the double-stranded RNA-binding domain of the protein kinase PKR reveals the molecular basis of its dsRNA-mediated activation. EMBO J. 1998;17:5458–5465. doi: 10.1093/emboj/17.18.5458.
    1. Nallagatla SR, et al. 5′-triphosphate-dependent activation of PKR by RNAs with short stem-loops. Science. 2007;318:1455–1458. doi: 10.1126/science.1147347.
    1. Hsu LC, et al. The protein kinase PKR is required for macrophage apoptosis after activation of Toll-like receptor 4. Nature. 2004;428:341–345. doi: 10.1038/nature02405.
    1. Gil J, et al. TRAF family proteins link PKR with NF-κB activation. Mol. Cell Biol. 2004;24:4502–4512. doi: 10.1128/MCB.24.10.4502-4512.2004.
    1. Gil J, Esteban M. The interferon-induced protein kinase (PKR), triggers apoptosis through FADD-mediated activation of caspase 8 in a manner independent of Fas and TNF-α receptors. Oncogene. 2000;19:3665–3674. doi: 10.1038/sj.onc.1203710.
    1. Saelens X, Kalai M, Vandenabeele P. Translation inhibition in apoptosis: caspase-dependent PKR activation and eIF2-α phosphorylation. J. Biol. Chem. 2001;276:41620–41628. doi: 10.1074/jbc.M103674200.
    1. Abraham N, et al. Characterization of transgenic mice with targeted disruption of the catalytic domain of the double-stranded RNA-dependent protein kinase, PKR. J. Biol. Chem. 1999;274:5953–5962. doi: 10.1074/jbc.274.9.5953.
    1. Yang YL, et al. Deficient signaling in mice devoid of double-stranded RNA-dependent protein kinase. EMBO J. 1995;14:6095–6106. doi: 10.1002/j.1460-2075.1995.tb00300.x.
    1. Scheuner D, et al. The double-stranded RNA-activated protein kinase mediates viral-induced encephalitis. Virology. 2003;317:263–274. doi: 10.1016/j.virol.2003.08.010.
    1. Ladiges W, et al. Expression of human PKR protein kinase in transgenic mice. J. Interferon Cytokine Res. 2002;22:329–334. doi: 10.1089/107999002753675758.
    1. Balachandran S, et al. Essential role for the dsRNA-dependent protein kinase PKR in innate immunity to viral infection. Immunity. 2000;13:129–141. doi: 10.1016/S1074-7613(00)00014-5.
    1. Stojdl DF, et al. The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J. Virol. 2000;74:9580–9585. doi: 10.1128/JVI.74.20.9580-9585.2000.
    1. Bergmann M, et al. Influenza virus NS1 protein counteracts PKR-mediated inhibition of replication. J. Virol. 2000;74:6203–6206. doi: 10.1128/JVI.74.13.6203-6206.2000.
    1. Noguchi T, et al. Effects of mutation in hepatitis C virus nonstructural protein 5A on interferon resistance mediated by inhibition of PKR kinase activity in mammalian cells. Microbiol. Immunol. 2001;45:829–840. doi: 10.1111/j.1348-0421.2001.tb01322.x.
    1. Chen CW, et al. The double-stranded RNA-activated kinase, PKR, can phosphorylate hepatitis D virus small δ antigen at functional serine and threonine residues. J. Biol. Chem. 2002;277:33058–33067. doi: 10.1074/jbc.M200613200.
    1. Samuel MA, et al. PKR and RNase L contribute to protection against lethal West Nile Virus infection by controlling early viral spread in the periphery and replication in neurons. J. Virol. 2006;80:7009–7019. doi: 10.1128/JVI.00489-06.
    1. Nagai K, et al. Induction of CD4 expression and human immunodeficiency virus type 1 replication by mutants of the interferon-inducible protein kinase PKR. J. Virol. 1997;71:1718–1725.
    1. Gorchakov R, Frolova E, Williams BR, Rice CM, Frolov I. PKR-dependent and -independent mechanisms are involved in translational shutoff during Sindbis virus infection. J. Virol. 2004;78:8455–8467. doi: 10.1128/JVI.78.16.8455-8467.2004.
    1. Yeung MC, Chang DL, Camantigue RE, Lau AS. Inhibitory role of the host apoptogenic gene PKR in the establishment of persistent infection by encephalomyocarditis virus in U937 cells. Proc. Natl Acad. Sci. USA. 1999;96:11860–11865. doi: 10.1073/pnas.96.21.11860.
    1. Chinsangaram J, Koster M, Grubman MJ. Inhibition of L-deleted foot-and-mouth disease virus replication by α/β interferon involves double-stranded RNA-dependent protein kinase. J. Virol. 2001;75:5498–5503. doi: 10.1128/JVI.75.12.5498-5503.2001.
    1. Al-khatib K, Williams BR, Silverman RH, Halford W, Carr DJ. The murine double-stranded RNA-dependent protein kinase PKR and the murine 2′, 5′-oligoadenylate synthetase-dependent RNase L are required for IFN-β-mediated resistance against herpes simplex virus type 1 in primary trigeminal ganglion culture. Virology. 2003;313:126–135. doi: 10.1016/S0042-6822(03)00298-8.
    1. Knapp S, et al. Polymorphisms in interferon-induced genes and the outcome of hepatitis C virus infection: roles of MxA, OAS-1 and PKR. Genes Immun. 2003;4:411–419. doi: 10.1038/sj.gene.6363984.
    1. Carritt B, et al. A gene from human chromosome region 3p21 with reduced expression in small cell lung cancer. Cancer Res. 1992;52:1536–1541.
    1. Kok K, et al. A gene in the chromosomal region 3p21 with greatly reduced expression in lung cancer is similar to the gene for ubiquitin-activating enzyme. Proc. Natl Acad. Sci. USA. 1993;90:6071–6075. doi: 10.1073/pnas.90.13.6071.
    1. Carpten J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nature Genet. 2002;30:181–184. doi: 10.1038/ng823.
    1. Urisman A, et al. Identification of a novel γ-retrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2006;2:e25. doi: 10.1371/journal.ppat.0020025.
    1. Silverman RH, et al. Skin allograft rejection is suppressed in mice lacking the antiviral enzyme, 2′, 5′-oligoadenylate-dependent RNase L. Viral Immunol. 2002;15:477–483. doi: 10.1089/088282402317340242.
    1. Field LL, et al. OAS1 splice site polymorphism controlling antiviral enzyme activity influences susceptibility to type 1 diabetes. Diabetes. 2005;54:1588–1591. doi: 10.2337/diabetes.54.5.1588.
    1. Bonnevie-Nielsen V, Larsen ML, Frifelt JJ, Michelsen B, Lernmark A. Association of IDDM and attenuated response of 2′, 5′-oligoadenylate synthetase to yellow fever vaccine. Diabetes. 1989;38:1636–1642. doi: 10.2337/diab.38.12.1636.
    1. Kumar A, Haque J, Lacoste J, Hiscott J, Williams BR. Double-stranded RNA-dependent protein kinase activates transcription factor NF-κB by phosphorylating IκB. Proc. Natl Acad. Sci. USA. 1994;91:6288–6292. doi: 10.1073/pnas.91.14.6288.
    1. Uetani K, et al. Central role of double-stranded RNA-activated protein kinase in microbial induction of nitric oxide synthase. J. Immunol. 2000;165:988–996. doi: 10.4049/jimmunol.165.2.988.
    1. Lee JH, et al. Double-stranded RNA-activated protein kinase is required for the LPS-induced activation of STAT1 inflammatory signaling in rat brain glial cells. Glia. 2005;50:66–79. doi: 10.1002/glia.20156.
    1. Karehed K, Dimberg A, Dahl S, Nilsson K, Oberg F. IFN-γ-induced upregulation of Fcγ-receptor-I during activation of monocytic cells requires the PKR and NF-κB pathways. Mol. Immunol. 2007;44:615–624. doi: 10.1016/j.molimm.2006.01.013.
    1. Lee SB, Esteban M. The interferon-induced double-stranded RNA-activated protein kinase induces apoptosis. Virology. 1994;199:491–496. doi: 10.1006/viro.1994.1151.
    1. Kadereit S, et al. Negative regulation of CD8+ T cell function by the IFN-induced and double-stranded RNA-activated kinase PKR. J. Immunol. 2000;165:6896–6901. doi: 10.4049/jimmunol.165.12.6896.
    1. Hardenberg G, et al. Specific TLR ligands regulate APRIL secretion by dendritic cells in a PKR-dependent manner. Eur. J. Immunol. 2007;37:2900–2911. doi: 10.1002/eji.200737210.
    1. Rager KJ, et al. Activation of antiviral protein kinase leads to immunoglobulin E class switching in human B cells. J. Virol. 1998;72:1171–1176.
    1. Bonnet MC, Weil R, Dam E, Hovanessian AG, Meurs EF. PKR stimulates NF-κB irrespective of its kinase function by interacting with the IκB kinase complex. Mol. Cell Biol. 2000;20:4532–4542. doi: 10.1128/MCB.20.13.4532-4542.2000.
    1. Haller O, Kochs G, Weber F. Interferon, Mx, and viral countermeasures. Cytokine Growth Factor Rev. 2007;18:425–433. doi: 10.1016/j.cytogfr.2007.06.001.
    1. Langland JO, Cameron JM, Heck MC, Jancovich JK, Jacobs BL. Inhibition of PKR by RNA and DNA viruses. Virus Res. 2006;119:100–110. doi: 10.1016/j.virusres.2005.10.014.
    1. Leib DA, Machalek MA, Williams BR, Silverman RH, Virgin HW. Specific phenotypic restoration of an attenuated virus by knockout of a host resistance gene. Proc. Natl Acad. Sci. USA. 2000;97:6097–6101. doi: 10.1073/pnas.100415697.

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner